{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:46:40Z","timestamp":1794376000315,"version":"4.9.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nanjing IASO Biotherapeutics Ltd","id":[{"id":"https:\/\/ror.org\/052rpve40","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) have great potentials in autoimmune diseases and could be novel therapeutics for relapsed\/refractory neuromyelitis optica spectrum disorder (NMOSD). To evaluate the safety and efficacy of the CT103A, a self-developed BCMA-targeting CAR construct against BCMA, in patients with AQP4-IgG seropositive NMOSD, an ongoing, investigator-initiated, open-label, single-arm, phase 1 clinical trial is conducted at our center. In total, 12 patients were administered with a CAR-BCMA infusion. Ten of the 12 patients dosed were women (83.3%), with a median age of 49.5 years (range, 30\u201367). were The most common events of grade 3 or higher were hematologic toxic effects. Seven patients (58%) developed infections, but no grade 4 infections occurred. Cytokine release syndrome was reported in all patients with only events of grade 1 or 2 observed. During the follow-up of a median 5.5 months, 11 patients had no relapse; all patients generally reported improvement in disabilities and quality-of-life outcomes; 11 patients\u2019 AQP-4 antibodies in serum showed a downward trend by the cutoff date. CAR T-cell expansion was associated with responses, and persisted more than 6 months post-infusion in 17% of the patients. In summary, CAR T-cell therapy shows a manageable safety profile and therapeutic potentials for patients with relapsed\/refractory AQP4-IgG seropositive NMOSD. Another expansion phase is currently underway to determine the safety and efficacy of CAR T-BCMA infusion in patients with other neuro-inflammatory diseases.<\/jats:p>","DOI":"10.1038\/s41392-022-01278-3","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T20:02:35Z","timestamp":1672776155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":182,"title":["Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results"],"prefix":"10.1038","volume":"8","author":[{"given":"Chuan","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-0811","authenticated-orcid":false,"given":"Dai-Shi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo-Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-3232","authenticated-orcid":false,"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-3020","authenticated-orcid":false,"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Bai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Tao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"1278_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius, S. et al. Neuromyelitis optica. Nat. Rev. Dis. Prim. 6, 85 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1278_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock, S. J., Zekeridou, A. & Weinshenker, B. G. Hope for patients with neuromyelitis optica spectrum disorders-from mechanisms to trials. Nat. Rev. Neurol. 17, 759\u2013773 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1278_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock, S. J. et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 614\u2013625 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1278_CR4","doi-asserted-by":"crossref","unstructured":"Graf, J. et al. Targeting B cells to modify MS, NMOSD, and MOGAD: Part 1. Neurol. Neuroimmunol. Neuroinflamm. 8, e918 (2021).","DOI":"10.1212\/NXI.0000000000000918"},{"key":"1278_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara, M. et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 19, 298\u2013306 (2020).","journal-title":"Lancet Neurol."},{"key":"1278_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394, 1352\u20131363 (2019).","journal-title":"Lancet"},{"key":"1278_CR7","doi-asserted-by":"crossref","unstructured":"Graf, J. et al. Targeting B cells to modify MS, NMOSD, and MOGAD: part 2. Neurol. Neuroimmunol. Neuroinflamm. 8, e919 (2021).","DOI":"10.1212\/NXI.0000000000000919"},{"key":"1278_CR8","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1535-7163.1493.3.11","volume":"3","author":"J Christiansen","year":"2004","unstructured":"Christiansen, J. & Rajasekaran, A. K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther. 3, 1493\u20131501 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"1278_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. & Kochenderfer, J. N. CAR T cell therapies for patients with multiple myeloma. Nat. Rev. Clin. Oncol. 18, 71\u201384 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1278_CR10","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137, 2890\u20132901 (2021).","journal-title":"Blood"},{"key":"1278_CR11","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1278_CR12","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","volume":"130","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 130, 6317\u20136324 (2020).","journal-title":"J. Clin. Invest."},{"key":"1278_CR13","doi-asserted-by":"crossref","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","DOI":"10.1038\/s41591-022-02017-5"},{"key":"1278_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1053\/j.seminoncol.2014.08.005","volume":"41","author":"I Caruana","year":"2014","unstructured":"Caruana, I., Diaconu, I. & Dotti, G. From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. Semin Oncol. 41, 661\u2013666 (2014).","journal-title":"Semin Oncol."},{"key":"1278_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","volume":"11","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J. Hematol. Oncol. 11, 128 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1278_CR16","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"1278_CR17","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/brain\/awab003","volume":"144","author":"J Walsh","year":"2021","unstructured":"Walsh, J. et al. Microglial activation and blood-brain barrier permeability in cerebral small vessel disease. Brain 144, 1361\u20131371 (2021).","journal-title":"Brain"},{"key":"1278_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy, M., Fujihara, K. & Palace, J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 20, 60\u201367 (2021).","journal-title":"Lancet Neurol."},{"key":"1278_CR19","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an Anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267\u20132280 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1278_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao, W. H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11, 141 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1278_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong, E. A., Ruella, M. & Schuster, S. J., Lymphoma Program Investigators at the University of, P. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N. Engl. J. Med. 384, 673\u2013674 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1278_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jneuroim.2015.05.007","volume":"283","author":"T Akaishi","year":"2015","unstructured":"Akaishi, T. et al. Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica. J. Neuroimmunol. 283, 70\u201373 (2015).","journal-title":"J. Neuroimmunol."},{"key":"1278_CR23","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/WNL.0b013e318229e694","volume":"77","author":"Y Kanamori","year":"2011","unstructured":"Kanamori, Y. et al. Pain in neuromyelitis optica and its effect on quality of life: a cross-sectional study. Neurology 77, 652\u2013658 (2011).","journal-title":"Neurology"},{"key":"1278_CR24","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura, T. et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 2114\u20132124 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1278_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee, A. et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 19, 402\u2013412 (2020).","journal-title":"Lancet Neurol."},{"key":"1278_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1278_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85, 177\u2013189 (2015).","journal-title":"Neurology"},{"key":"1278_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1620\/tjem.210.307","volume":"210","author":"T Takahashi","year":"2006","unstructured":"Takahashi, T. et al. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J. Exp. Med. 210, 307\u2013313 (2006).","journal-title":"Tohoku J. Exp. Med."},{"key":"1278_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"1278_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1278_CR31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","volume":"22","author":"Y Lou","year":"2020","unstructured":"Lou, Y. et al. Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital PCR versus real-time PCR. J. Mol. Diagn. 22, 699\u2013707 (2020).","journal-title":"J. Mol. Diagn."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01278-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:04:48Z","timestamp":1672920288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-01278-3","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"1 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wen W. held interests in patent applications related to the CT103A. Wen W., S.-B.C., J.-J.G., and H.P. are employees of Nanjing IASO Therapeutics Ltd. and held interests in the company. All other authors declared no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}